Literature DB >> 30080983

Vancomycin concentrations in the cervical spine after intravenous administration: results from an experimental pig study.

Mats Bue1,2, Pelle Hanberg1,2, Mikkel Tøttrup3,4, Maja B Thomassen2, Hanne Birke-Sørensen2, Theis M Thillemann2,4, Torben L Andersson5, Kjeld Søballe2,4.   

Abstract

Background and purpose - Vancomycin may be an important drug for intravenous perioperative antimicrobial prophylaxis in spine surgery. We assessed single-dose vancomycin intervertebral disc, vertebral cancellous bone, and subcutaneous adipose tissue concentrations using microdialysis in a pig model. Material and methods - 8 female pigs received 1,000 mg of vancomycin intravenously as a single dose over 100 minutes. Microdialysis probes were placed in the C3-C4 intervertebral disc, C3 vertebral cancellous bone, and subcutaneous adipose tissue, and vancomycin concentrations were obtained over 8 hours. Venous blood samples were obtained as reference. Results - Ranging from 0.24 to 0.60, vancomycin tissue penetration, expressed as the ratio of tissue to plasma area under the concentration-time curve from 0 to the last measured value, was incomplete for all compartments. The lowest penetration was found in the intervertebral disc. The time to a mean clinically relevant minimal inhibitory concentration (MIC) of 4 µg/mL was 3, 17, 25, and 156 min for plasma, subcutaneous adipose tissue, vertebral cancellous bone, and the intervertebral disc, respectively. In contrast to the other compartments, a mean MIC of 8 µg/mL was not reached in the intervertebral disc. An approximately 3-times longer elimination rate was observed in the intervertebral disc in comparison with all the other compartments (p < 0.001), and the time to peak drug concentration was higher for all tissues compared with plasma Interpretation - Preoperative administration of 1,000 mg of vancomycin may provide adequate vancomycin tissue concentrations with a considerable delay, though tissue penetration was incomplete. However, in order also to achieve adequate intervertebral disc concentrations in all individuals and accommodating a potentially higher MIC target, supplemental application of vancomycin may be necessary.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30080983      PMCID: PMC7025694          DOI: 10.1080/17453674.2018.1501548

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


Postoperative surgical site infections following spine surgery can have devastating complications such as mechanical fixation failure, neurological injury, pseudoarthrosis, and sepsis (Fang et al. 2005). The reported incidence of postoperative spondylodiscitis ranges between 1% and 4% and may be even higher when instrumentation is applied (Gaynes et al. 2001, Deyo et al. 2004, Fang et al. 2005, Smith et al. 2011). Perioperative antimicrobial prophylaxis plays a key role in lowering the risk of postoperative spondylodiscitis. The antimicrobial effect relies not only on its sensitivity against the invading bacteria, but also on adequate target site concentrations. For vancomycin, tissue targets for prevention of postoperative spondylodiscitis have not been established. Nonetheless, it seems prudent to maintain tissue concentrations that, as a minimum, exceed minimal inhibitory concentrations (MIC) of relevant bacteria throughout surgery and until a few hours after the incision is closed (Mangram et al. 1999, Whiteside 2016). Vancomycin may become increasingly important as perioperative antimicrobial prophylaxis in spine surgery due to the increasing incidence of methicillin-resistant Staphylococcus aureus (MRSA) infections (Al-Nammari et al. 2007, Gouliouris et al. 2010). However, routine use of vancomycin is not indicated due to the risk of resistance development (Mangram et al. 1999, Bryson et al. 2016). Incomplete vancomycin penetration has recently been reported for a number of tissues (Bue et al. 2018a, b). Given the avascular nature of the intervertebral disc, vancomycin penetration may be inadequate for optimal prevention of postoperative spondylodiscitis. It is challenging to determine antimicrobial spine tissue concentrations. Intervertebral disc and bone concentrations of vancomycin have almost only been evaluated using bone and disc tissue samples and discectomy (Scuderi et al. 1993, Conaughty et al. 2006, Landersdorfer et al. 2009, Komatsu et al. 2010). However, these methods suffer from methodological challenges, which makes it difficult to relate the results to relevant pharmacokinetic/pharmacodynamic endpoints (Landersdorfer et al. 2009, Pea 2009). Recently, microdialysis has evolved as a promising method for sampling various antimicrobials in different types of tissues, including bone and the intervertebral disc (Stolle et al. 2004, Bue et al. 2015, Tottrup et al. 2015, Hanberg et al. 2016, Bue et al. 2018a, b). We assessed single-dose vancomycin concentrations in the C3–C4 intervertebral disc, the C3 vertebral cancellous bone, and subcutaneous adipose tissue using microdialysis in a pig model mimicking a perioperative situation. Tissue penetration ratios, expressed as the ratio of tissue to plasma area under the concentration-time curve from 0 to the last measured value (AUCtissue/AUCplasma), and time to mean MICs of 2, 4, and 8 µg/mL were the primary endpoints. The secondary endpoints were pharmacokinetic parameters: the area under the concentration-time curves (AUC0–last), peak drug concentration (Cmax), time to Cmax (Tmax), and half-life (T1/2).

Material and methods

This study was conducted at the Institute for Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. All chemical analyses were performed at the Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.

Overview

8 female pigs were included in the study (Danish Landrace Breed; weight 78–82 kg). Vancomycin was administered intravenously as a single dose of 1,000 mg over 100 min, and sampling was conducted over 8 hours starting at the beginning of vancomycin infusion. Vancomycin concentrations were obtained using microdialysis in the C3–C4 intervertebral disc, the C3 vertebral cancellous bone, and subcutaneous adipose tissue.

Anesthesia and surgical procedures

The pigs were kept under general anesthesia using a combination of fentanyl (0.35–0.5 mg/h, continuous infusion) and propofol (500–600 mg/h, continuous infusion) during the surgery and the sampling period. Arterial pH was monitored throughout the study and kept in the range of 7.36–7.47 by regulating ventilation. Blankets were used to keep the core temperatures within the range of 36.2–39.1 °C. Immediately after induction of anesthesia, the surgical procedures were initiated. With the pig in supine position, and under fluoroscopic guidance, the C2–C4 vertebrae were exposed via an anterolateral incision. At approximately 45° to the sagittal plane, a drill hole with a diameter of 2 mm and a depth of 25 mm was created in the middle of C3. Parallel to this drill hole, a Kirschner wire with a fixating device (PEBAX, M Dialysis AB, Stockholm, Sweden) was drilled into the caudal part of C2. A microdialysis probe (membrane length 20 mm) was inserted into a splittable introducer with the membrane protruding approximately 30 mm from the tip of the introducer. This probe-introducer setup was then placed in the drill hole in C3 and fixed to the fixating device; an endo clip was then attached to the introducer. These steps were taken to avoid subsequent displacement of the probe. At the same angle, a splittable introducer with a needle was introduced into the intervertebral disc between C3 and C4 parallel to, and in the middle of, the adjacent endplates. After the annulus fibrosus was penetrated, the needle was retracted, and the introducer was carefully advanced into the nucleus pulposus until resistance from the opposite wall of the annulus fibrosus was felt. A microdialysis probe (membrane length 10 mm) was then placed in the introducer, and the splittable introducer was retracted until the entire membrane of the probe was exposed in the intervertebral disc. The probe was attached to the introducer with endo clips. Fluoroscopy was used to assess correct location of the probes in the C3 vertebral body and the C3–C4 intervertebral disc. In addition to the bone and intervertebral disc probes, a subcutaneous adipose tissue probe (membrane length 20 mm) was placed in the lateral part of the right thigh, based on the manufacturer’s guidelines.

Microdialysis and sampling procedures

A detailed description of microdialysis can be found elsewhere (Muller 2002, Joukhadar and Muller 2005). Briefly, microdialysis is a probe-based method that allows for serial sampling of water-soluble molecules from the extracellular fluid in the tissue of interest by means of a semipermeable membrane at the tip of the microdialysis probe (Joukhadar et al. 2001, Hutschala et al. 2013). Due to continuous perfusion of the probe, a non-equilibrium diffusion of molecules following the concentration gradient will occur. Consequently, the concentration in the dialysate represents only a fraction of the true tissue concentration, which is expressed as the relative recovery. Thus, relative recovery must be determined to calculate the absolute tissue concentrations. In the present study, all the microdialysis probes were individually calibrated at the end of the study using the retrodialysis by drug method (Scheller and Kolb 1991). The relative recovery was calculated using the following Equation 1: where Cdialysate is the concentration (µg/mL) in the dialysate and Cperfusate is the concentration (µg/mL) in the perfusate. Absolute, extracellular concentrations (µg/mL), Ctissue, were calculated by correcting for relative recovery using the following Equation 2: The microdialysis system consisted of CMA 107 precision pumps (M Dialysis AB, Stockholm, Sweden) and CMA 70 probes (membrane length 20 mm and 10 mm, molecular cut-off 20 kilo Daltons). All the microdialysis probes were perfused with 0.9% NaCl at a perfusion rate of 1 µL/min throughout the sampling time. Following a 30-min tissue equilibration period after placement of the microdialysis probes, 1,000 mg of vancomycin was administered intravenously over 100 min starting at time zero. For the first 2 hours, dialysates were harvested at 40-min intervals and, thereafter, at 60-min intervals for the following 6 hours, resulting in a total of nine samples over 8 hours. The relative recovery-corrected dialysate concentrations were ascribed to the midpoint of each sampling interval. Venous blood samples were harvested from a central venous catheter at the midpoint of the same 9 sampling intervals. When the last dialysate was collected, all the probes were individually calibrated using 0.9% NaCl with vancomycin at a concentration of 300 µg/mL by collecting 60-min samples. This high calibration concentration of vancomycin was chosen to minimize the influence of the residual local tissue concentrations. After the last dialysates were collected, the pigs were killed using pentobarbital. The dialysates were immediately placed in a –80 °C freezer until analysis. The venous blood samples were stored at 5 °C for a maximum of eight hours before being centrifuged at 3,000 g for 10 minutes. The plasma aliquots were then frozen and stored at –80 °C until analysis.

Chemical analysis of vancomycin

The vancomycin concentrations in the dialysates were quantified using ultra-high-performance liquid chromatography as previously described (Bue et al. 2015). The quantification limit was defined as the lowest concentration with intra-run CV <20%; it was found to be 0.05 µg/mL. The free concentration of vancomycin in plasma was measured with a homogeneous enzyme immunoassay technique using the Siemens Chemistry XPT platform (Advia Chemistry, Erlangen, Germany). Intra-run (total) imprecisions for the assay were ±1.2 µg/mL (2SD) at 6.6 µg/mL and ±3.7 µg/mL (2SD) at 29.1 µg/mL.

Pharmacokinetic analysis and statistics

Using Microsoft Excel (Microsoft Corp, Redmond, WA, USA), the time to mean clinically relevant MICs of 2, 4, and 8 µg/mL was estimated using linear interpolation. The pharmacokinetic parameters, AUC0–last, Cmax, Tmax, and T1/2, were determined separately for each compartment for each pig by non-compartmental analysis using the pharmacokinetic-series of commands in Stata (v. 14.1, StataCorp LLC, College Station, TX, USA). The AUC0–last was calculated using the trapezoidal rule. The tissue AUC0–last to plasma AUC0–last ratio (AUCtissue/AUCplasma) was calculated as a measure of tissue penetration. Cmax was calculated as the maximum of all the recorded concentrations and Tmax was calculated as the time to Cmax. T1/2 was calculated as ln(2)/λeq, where λeq is the terminal elimination rate constant estimated by linear regression of the log concentration on time. These pharmacokinetic parameters were obtained in all 4 compartments from the same pig and a mixed model for repeated measurements had compartments as fixed effect and subject identification variable as a random effect was applied. Also, distinct residual variance was assumed within each compartment. The normality of the residuals was estimated using a quantile–quantile (QQ) plot for the residuals and the homogeneity of the residual variance was checked by plotting residuals vs. best linear unbiased prediction estimates. The normality of the estimated random effects was checked using a QQ plot of the estimated random effects. A correction for degrees of freedom due to small sample size was handled using the Kenward–Roger approximation method. The F-test was used to determine the overall comparisons between the compartments and the t-test was used to determine pairwise comparisons. A p-value <0.05 was considered to be significant. Statistical analyses were also performed using Stata. Values below the lower limit of quantification were set to zero. The means and 95% CI of AUC0–last, Cmax, Tmax, and T1/2 are presented in the Table.

Table: Pharmacokinetic parameters for plasma, subcutaneous adipose tissue, vertebral cancellous bone, and intervertebral disc

TissueAUC0–last (min µg/mL)Cmax (µg/mL)Tmax (min)T1/2 (min)AUCtissue/AUCplasma
Plasma (unbound)7,880 (7164–8597) b40.0 (35.7–44.3) b75 (61–89)325 (99–552) 
Subcutaneous adipose tissue4,719 (4002–5436)18.0 (14.1–21.9)113 (96–129)224 (197–250)0.60 (0.48–0.72)
Vertebral cancellous bone3,677 (2960–4393) c12.3 (9.6–15.0) c159 (134–184)271 (227–315)0.46 (0.40–0.53)
Intervertebral disc1,983 (1237–2729) d6.6 (3.6–9.6)4270 (187–353)933 (527–1,339) e0.24 (0.17–0.31)
p-valuea< 0.001< 0.001< 0.008 

Values are given as means (95% confidence interval).

AUC0–last, area under the concentration-time curve from 0 to the last measured value; Cmax, peak drug concentration; Tmax, time to Cmax; T1/2, half-life at β-phase; AUCtissue/AUCplasma, tissue penetration expressed as the ratio of AUCtissue/AUCplasma.

Overall comparison using F test for plasma (unbound), subcutaneous adipose tissue, vertebral cancellous bone, and intervertebral disc.

p < 0.001 for all comparisons between plasma and the other compartments.

p < 0.01 for comparison with subcutaneous adipose tissue.

p < 0.01 for comparison between intervertebral disc and the other compartments.

p < 0.001 for all comparisons between intervertebral disc and the other compartments.

Table: Pharmacokinetic parameters for plasma, subcutaneous adipose tissue, vertebral cancellous bone, and intervertebral disc Values are given as means (95% confidence interval). AUC0–last, area under the concentration-time curve from 0 to the last measured value; Cmax, peak drug concentration; Tmax, time to Cmax; T1/2, half-life at β-phase; AUCtissue/AUCplasma, tissue penetration expressed as the ratio of AUCtissue/AUCplasma. Overall comparison using F test for plasma (unbound), subcutaneous adipose tissue, vertebral cancellous bone, and intervertebral disc. p < 0.001 for all comparisons between plasma and the other compartments. p < 0.01 for comparison with subcutaneous adipose tissue. p < 0.01 for comparison between intervertebral disc and the other compartments. p < 0.001 for all comparisons between intervertebral disc and the other compartments.

Ethics, funding, and potential conflicts of interest

The study was approved by the Danish Animal Experiments Inspectorate and carried out according to existing laws (license No. 2017/15-0201-01184). This work was supported by unrestricted grants from the Augustinus Foundation, the Lippmann Foundation, the Knud and Edith Eriksens Memorial Foundation, the Søster and Verner Lipperts Foundation, and the Health Research Fund of Central Denmark Region. No competing interests were declared.

Results

All 8 pigs completed the study. Except for one malfunctioning intervertebral disc probe, data were obtained from all probes. Fluoroscopy confirmed correct placement of all of the probes (Figure 1). Mean (SD) relative recovery for the intervertebral disc, vertebral cancellous bone, and subcutaneous adipose tissue was 16% (6), 36% (4), and 33% (5), respectively.
Figure 1.

Representative fluoroscopic image showing the location of the microdialysis (MD) probes in a sagittal view: the Kirschner wire with the fixating device in the C2 vertebral body, C3 and C4 vertebral body, C3–C4 intervertebral disc (IVD), the gold thread within the microdialysis probe membrane tip in the vertebral cancellous bone (VCB) and intervertebral disc.

Representative fluoroscopic image showing the location of the microdialysis (MD) probes in a sagittal view: the Kirschner wire with the fixating device in the C2 vertebral body, C3 and C4 vertebral body, C3–C4 intervertebral disc (IVD), the gold thread within the microdialysis probe membrane tip in the vertebral cancellous bone (VCB) and intervertebral disc. Tissue penetration (AUCtissue/AUCplasma) of vancomycin (95% CI) was incomplete for the subcutaneous adipose tissue 0.60 (0.48–0.72), vertebral cancellous bone 0.46 (0.40–0.53), and intervertebral disc 0.24 (0.17–0.31). After 15 min, a mean concentration of 2 µg/mL (MIC) was reached in all compartments. The time to a mean MIC of 4 µg/mL was 3, 17, 25, and 156 min for plasma, subcutaneous adipose tissue, vertebral cancellous bone, and the intervertebral disc, respectively. A mean MIC of 8 µg/mL could not be reached in the intervertebral disc, whereas it was reached after 7, 37, and 81 min in plasma, subcutaneous adipose tissue, and vertebral cancellous bone, respectively. The vancomycin tissue and plasma concentration-time profiles are shown in Figure 2. The pharmacokinetic parameters are presented in the Table. Cmax (95% CI) was 6.6 µg/mL (3.6–9.6) for the intervertebral disc, 12 µg/mL (9.6–15) for vertebral cancellous bone, 18 µg/mL (14–22) for subcutaneous adipose tissue, and 40 µg/mL (36–44) for plasma. The Tmax findings revealed delayed tissue penetration, particularly to the intervertebral disc and vertebral cancellous bone. Furthermore, T1/2 was approximately 3 times longer in the intervertebral disc in comparison with the other compartments (p < 0.001). Finally, AUC0–last and Cmax were lower in the intervertebral disc than in the vertebral cancellous bone (p < 0.01).
Figure 2.

Mean concentration-time profiles for plasma, subcutaneous adipose tissue, vertebral cancellous bone, and the intervertebral disc. Bars represent 95% confidence intervals. MICs of 2, 4, and 8 µg/mL are also inserted.

Mean concentration-time profiles for plasma, subcutaneous adipose tissue, vertebral cancellous bone, and the intervertebral disc. Bars represent 95% confidence intervals. MICs of 2, 4, and 8 µg/mL are also inserted.

Discussion

To our knowledge, this is the first study to investigate single-dose vancomycin intervertebral disc and vertebral cancellous bone concentrations using microdialysis. Insufficient perioperative antimicrobial target site penetration might play an important role for the rather high incidence of postoperative spondylodiscitis. A key finding of this study was therefore incomplete and delayed intervertebral disc and vertebral cancellous bone penetration of vancomycin, with the lowest and most delayed penetration found in the intervertebral disc. However, using standard recommendations for prevention of surgical site infections and planktonic MICs of commonly encountered bacteria in spine surgery (0.5–4 µg/mL), adequate mean concentrations were achieved in all compartments, although a considerable delay was found in the intervertebral disc (Gouliouris et al. 2010, EUCAST 2017). Advantageously for a perioperative prophylactic setting, it should be noted that an approximately 3 times longer vancomycin elimination rate was found in the intervertebral disc in comparison with the other compartments. Thus, if vancomycin is administrated in due time, adequate intervertebral disc concentrations may be sustained throughout even long surgical procedures and for some time after. This makes vancomycin attractive because it continues to kill bacteria even after surgery has ended. On the other hand, our data suggest a rather narrow or no margin at all in individuals with low intervertebral disc concentrations to bacteria exhibiting high MICs. Moreover, in the case of MRSA, increasing vancomycin MICs have been demonstrated over the last decades (Steinkraus et al. 2007). The traditional target recommendations for prevention of surgical site infections lack scientific evaluation and may in fact be insufficient for spine surgery, particularly when considering the possible devastating complications of infection in spine surgery. Higher and prolonged tissue concentrations cannot be achieved by means of increasing intravenous vancomycin doses as this is restricted by toxicity (Rybak et al. 2009). Consequently, our findings call for some considerations regarding vancomycin dosing, timing, and administration in the perioperative spine setting. Preoperative administration of 1,000 mg of vancomycin may provide adequate vancomycin tissue concentrations with a considerable delay. However, in order also to achieve adequate intervertebral disc concentrations in all individuals and accommodating a potentially higher MIC target, supplemental application (e.g. as perioperative powder) of vancomycin may be necessary (Murphy et al. 2017). Incomplete and heterogeneous tissue distribution of antimicrobials has been demonstrated for a diverse combination of drugs and tissues and under different conditions, including infections (Joukhadar et al. 2001, Joukhadar and Muller 2005, Schintler et al. 2009, Hutschala et al. 2013, Tottrup et al. 2015, 2016). In our study, the tissue penetration ratios for vancomycin were lower for all tissues in comparison with an analogous cefuroxime study (Hanberg et al. 2016). These findings suggest that the choice of antimicrobial prophylaxis should not only be based on the characteristics of the infectious bacteria and plasma pharmacokinetics, but also on the tissue pharmacokinetics for the specific drug and the specific setting. In terms of infected tissue, it has previously been shown that vancomycin bone penetration may decrease with progression of an infection (Bue et al. 2018a). This emphasizes the need for spine tissue pharmacokinetic studies of relevant antimicrobials under different conditions. The penetration of vancomycin into a human intervertebral disc may vary from our findings in the study, as juvenile pigs (aged 5 months) differ from adult humans in several ways (Alini et al. 2008). First, blood vessels in the human annulus fibrosus are only present in the first part of life; thereafter, the perfusion relies upon only diffusion from the endplates (Roberts et al. 2006, Gouliouris et al. 2010). Second, the intervertebral disc is thinner in pigs than in humans, indicating shorter diffusion distances (Alini et al. 2008). Third, the body mass and weight-bearing impact on the vertebral bodies and intervertebral disc differs between humans and pigs. Moreover, higher vancomycin concentrations have been demonstrated in pig bone and tissue concentrations in comparison with male patients undergoing total knee replacement surgery (Bue et al. 2015, Bue et al. 2018b). Until now, vancomycin bone and intervertebral disc concentrations have only been assessed using bone and disc tissue samples and discectomy (Scuderi et al. 1993, Conaughty et al. 2006, Landersdorfer et al. 2009, Komatsu et al. 2010). In contrast, microdialysis allows for serial sampling of the unbound extracellular concentrations of drug in bone and in the intervertebral disc, and it provides dynamic concentration-time profiles (Joukhadar and Muller 2005, Hanberg et al. 2016). Therefore, the pharmacokinetic parameters obtained by microdialysis are useful for evaluating pharmacodynamic/pharmacokinetic targets. In addition to the inherent inter-species limitations of a porcine study, a certain methodological aspect of the microdialysis approach should be considered when evaluating microdialysis data. Thus, to obtain absolute tissue concentrations, the actual measured concentrations are corrected for relative recovery. This leads to a magnification of the variations associated with pre-analytical sample handling and chemical assay. These variations will increase exponentially as the relative recovery decreases. The variances in plasma and tissue pharmacokinetics found in the present study were comparable, indicating acceptable precision of the measurements within the biological variation. In summary, vancomycin penetration into healthy pig intervertebral disc and vertebral cancellous bone was found to be incomplete and delayed, with the lowest and most delayed penetration to the intervertebral disc. However, applying standard recommendations for prevention of postoperative spondylodiscitis, preoperative administration of 1,000 mg of vancomycin may provide adequate vancomycin tissue concentrations with a considerable delay. Nonetheless, in order also to achieve adequate intervertebral disc concentrations in all individuals and accommodating a potentially higher MIC target, supplemental application of vancomycin may be necessary. Validation of these findings in a clinical setting is warranted. MB, PH, MT, MBT, HBS, TMT, and KS initiated and designed the study. MB, MBT, and PH conducted the surgery and MB placed all the probes. MB, MBT, and PH collected the data. TLA performed the chemical analyses. Statistical analysis and interpretation of data was done by MB, PH, MT, HBS, TMT, TLA, and KS. All authors drafted and revised the manuscript. Acta thanks Volker Alt and Ivar Rossvoll for help with peer review of this study.
  32 in total

Review 1.  Science, medicine, and the future: Microdialysis.

Authors:  Markus Müller
Journal:  BMJ       Date:  2002-03-09

2.  Surgical site infection (SSI) rates in the United States, 1992-1998: the National Nosocomial Infections Surveillance System basic SSI risk index.

Authors:  R P Gaynes; D H Culver; T C Horan; J R Edwards; C Richards; J S Tolson
Journal:  Clin Infect Dis       Date:  2001-09-01       Impact factor: 9.079

3.  Application of microdialysis to cancellous bone tissue for measurement of gentamicin levels.

Authors:  Lars B Stolle; Magnus Arpi; Peter Holmberg-Jørgensen; Per Riegels-Nielsen; Johnny Keller
Journal:  J Antimicrob Chemother       Date:  2004-06-09       Impact factor: 5.790

4.  Hematogenous methicillin-resistant Staphylococcus aureus spondylodiscitis.

Authors:  Shafic Said Al-Nammari; Jonathan D Lucas; Khai S Lam
Journal:  Spine (Phila Pa 1976)       Date:  2007-10-15       Impact factor: 3.468

5.  The internal reference technique in microdialysis: a practical approach to monitoring dialysis efficiency and to calculating tissue concentration from dialysate samples.

Authors:  D Scheller; J Kolb
Journal:  J Neurosci Methods       Date:  1991-11       Impact factor: 2.390

6.  Efficacy of linezolid versus vancomycin in the treatment of methicillin-resistant Staphylococcus aureus discitis: a controlled animal model.

Authors:  Jason M Conaughty; Jack Chen; Octavio V Martinez; Gino Chiappetta; Kathleen F Brookfield; Frank J Eismont
Journal:  Spine (Phila Pa 1976)       Date:  2006-10-15       Impact factor: 3.468

7.  A review of the application of vancomycin powder to posterior spinal fusion wounds with a focus on side effects and infection. A prospective study.

Authors:  Evelyn P Murphy; Mark Curtin; Aseer Shafqat; Fergus Byrne; Mutaz Jadaan; Elias Rahall
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-11-17

Review 8.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.

Authors:  Michael V Schintler; Friederike Traunmüller; Julia Metzler; Gerhard Kreuzwirt; Stephan Spendel; Oliver Mauric; Martin Popovic; Erwin Scharnagl; Christian Joukhadar
Journal:  J Antimicrob Chemother       Date:  2009-07-03       Impact factor: 5.790

10.  Effects of Implant-Associated Osteomyelitis on Cefuroxime Bone Pharmacokinetics: Assessment in a Porcine Model.

Authors:  Mikkel Tøttrup; Mats Bue; Janne Koch; Louise Kruse Jensen; Pelle Hanberg; Bent Aalbæk; Kurt Fuursted; Henrik Elvang Jensen; Kjeld Søballe
Journal:  J Bone Joint Surg Am       Date:  2016-03-02       Impact factor: 5.284

View more
  3 in total

1.  Single-dose pharmacokinetics of meropenem in porcine cancellous bone determined by microdialysis: An animal study.

Authors:  Pelle Hanberg; Andrea Lund; Kjeld Søballe; Mats Bue
Journal:  Bone Joint Res       Date:  2019-08-02       Impact factor: 5.853

2.  Tibial bone and soft-tissue concentrations following combination therapy with vancomycin and meropenem - evaluated by microdialysis in a porcine model : should patients with open fractures have higher doses of antibiotics?

Authors:  Sofus Ørbæk Vittrup; Pelle Hanberg; Martin Bruun Knudsen; Sara Kousgaard Tøstesen; Josephine Olsen Kipp; Jakob Hansen; Nis Pedersen Jørgensen; Maiken Stilling; Mats Bue
Journal:  Bone Joint Res       Date:  2022-02       Impact factor: 5.853

3.  Intermittent Short-Term Infusion vs. Continuous Infusion of Piperacillin: Steady State Concentrations in Porcine Cervical Spine Tissue Evaluated by Microdialysis.

Authors:  Elisabeth Krogsgaard Petersen; Pelle Hanberg; Martin Knudsen; Sara Kousgaard Tøstesen; Andrea René Jørgensen; Kristina Öbrink-Hansen; Kjeld Søballe; Maiken Stilling; Mats Bue
Journal:  Antibiotics (Basel)       Date:  2022-07-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.